HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer

HUTCHMED initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s tislelizumab in patients with advanced triple negative breast cancer or advanced endometrial cancer in the US. This trial is to explore the potential for the addition of a highly selective vascular endothelial growth factor receptor inhibitor, fruquintinib, to anti-programmed death-1 antibody tislelizumab in inducing activity to immune checkpoint inhibitors.